scholarly journals Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tianli Hui ◽  
Chao Shang ◽  
Liu Yang ◽  
Meiqi Wang ◽  
Ruoyang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Cancer Patients ◽  
Diabetes Group ◽  
Metformin Group

AbstractEarly reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus

Tumor Biology ◽  
2016 ◽  
Vol 37 (8) ◽  
pp. 11057-11063 ◽  
Author(s):  
Shu Zhang ◽  
Ling-Ji Guo ◽  
Gang Zhang ◽  
Ling-Li Wang ◽  
Shuai Hao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals MON-678 Worsening Diabetes Control in Breast Cancer Patients Treated with Alpelisib

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Robert Geier ◽  
Nisreen Abu Al Hommos ◽  
Ebenezer A Nyenwe ◽  
Anita Eapen
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Adverse Effect ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Cancer Patients ◽  
Pi3k Inhibitor ◽  
Breast Cancer Patients

Abstract Introduction: A new phosphatidylinositol-3-kinase (PI3K) inhibitor, alpelisib (Piqray) has been recently approved for the treatment of breast cancer. Severe hyperglycemia has been reported as an adverse effect. Many breast cancer patients also have diabetes mellitus type 2 which puts them at a higher risk for this adverse effect.1 2 Case description: Patient is a 73 year old Caucasian woman with history of insulin treated type 2 diabetes mellitus and breast cancer who presented to the hospital with a left hip fracture. She has been recently started on alpelisib with worsening glycemic control. Glycemic control improved after alpelisib was held for 5 days. She resumed taking alpelisib and had an up titration of the insulin regimen. During her hospital stay, she suffered from hyperglycemia as high as 558 mg/dl. HbA1c increased to 11.3% from 6.5% reportedly before starting alpelisib. Patient was discharged on an intensified regimen with close follow up. Discussion: Alpelisib is a PI3K inhibitor used in the treatment of postmenopausal women and men with hormone receptor positive, human epidermal growth factor receptor-2 negative, PIK3CA-mutated metastatic breast cancer. It inhibits PI3K which in turn inhibits protein kinase B (AKT). Insulin binds to insulin receptor substrates which activates PI3K, which in turn activates AKT resulting in translocation of the glucose transporter GLUT4 to the plasma membrane causing an uptake of glucose.3 A disruption in this pathway will result in hyperglycemia. Hyperglycemia was reported in 65% of patients with some cases found to be in ketoacidosis. This adverse effect means frequent monitoring of blood glucose is required following initiation of this treatment.4 Conclusion: Alpelisib is a new drug used in the select treatment of breast cancer. It can cause severe hyperglycemia and potential worsening of diabetes. Blood glucose should be monitored closely in patients with diabetes who are treated with alpelisib. References: Giovannucci E et al. Diabetes and Cancer. A consensus report. Diabetes Care 33:1674–1685, 2010. Boyle P et al. Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 107, 1608–1617, 2012. Huang, X et al. The PI3K/AKT pathway in obesity and type 2 diabetes. International Journal of Biological Sciences14,1483–1496,2018. Piqray [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp;2019

Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes

Breast Cancer ◽  
2019 ◽  
Vol 26 (6) ◽  
pp. 712-718 ◽  
Author(s):  
Na Li ◽  
Xin-hai Lv ◽  
Xin Wang ◽  
Rui-tao Wang ◽  
Yuan-xi Huang
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Mean Platelet Volume ◽  
Breast Cancer Patients ◽  
Platelet Volume
Sign in / Sign up

Export Citation Format

Share Document